Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:30473.

Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia

Jatinder K. Lamba _, Xueyuan Cao, Susana C. Raimondi, Roya Rafiee, James R. Downing, Lei Shi, Tanja Gruber, Raul C. Ribeiro, Jeffrey E. Rubnitz and Stanley B. Pounds

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:26711-26723. https://doi.org/10.18632/oncotarget.25475

Metrics: PDF 1872 views  |   HTML 3062 views  |   ?  


Abstract

Jatinder K. Lamba1, Xueyuan Cao2, Susana C. Raimondi3, Roya Rafiee1, James R. Downing3, Lei Shi2, Tanja Gruber4, Raul C. Ribeiro4, Jeffrey E. Rubnitz4 and Stanley B. Pounds2

1Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA

2Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA

3Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA

4Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA

Correspondence to:

Jatinder K. Lamba, email: [email protected]

Keywords: AML; methylation; pediatrics; leukemia

Received: February 16, 2018     Accepted: May 10, 2018     Published: June 01, 2018

ABSTRACT

Acute myeloid leukemia (AML) may be an epigenetically-driven malignancy because it harbors fewer genomic mutations than other cancers. In recent studies of AML in adults, DNA methylation patterns associate with clinical risk groups and prognosis. However, thorough evaluations of methylation in pediatric AML have not been done. Therefore, we performed an integrated analysis (IA) of the methylome and transcriptome with clinical outcome in 151 pediatric patients from the multi-center AML02 clinical trial discovery cohort. Intriguingly, reduced methylation and increased expression of DNMT3B was associated with worse clinical outcomes (IA p ≤ 10−5; q ≤ 0.002). In particular, greater DNMT3B expression associated with worse minimal residual disease (MRD; p < 10−5; q = 0.01), a greater rate of relapse or resistant disease (RR) (p = 0.00006; q = 0.06), and event-free survival (EFS; p = 0.00003; q = 0.04). Also, greater DNMT3B expression associated with greater genome-wide methylation burden (GWMB; R = 0.39; p = 10−6) and greater GWMB associated with worse clinical outcomes (IA p < 10−5). In an independent validation cohort of 132 similarly treated AAML0531 clinical trial patients, greater DNMT3B expression associated with greater GWMB, worse MRD, worse RR, and worse EFS (all p < 0.03); also, greater GWMB associated with worse MRD (p = 0.004) and EFS (p = 0.037). These results indicate that DNMT3B and GWMB may have a central role in the development and prognosis of pediatric AML.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25475